Endovascular treatment in acute ischemic stroke by Andonova, Silva et al.
26  Scripta Scientifica Medica, vol. 46, No 1, 2014, 26-29
Copyright © Medical University of Varnaa
REVIEWS
ENDOVASCULAR TREATMENT IN ACUTE ISCHEMIC 
STROKE
Silva Andonova¹, Zvetomila Dimitrova¹,  Еvgenia Кalevska¹, Мarina Petkova¹,  
Vania Аrgirova¹, Penka Кirilova¹, Zvetan Zvetkov¹, Мarianna Novakova²,  
Radoslav Georgiev²
¹Department of Neurology, Medical University of Varna, ²Centre of Radiology,  
St. Marina University Hospital of Varna
ABSTRACT
 Stroke remains a major health care challenge worldwide and is the third leading cause of death and the lead-
ing cause of disability in developed countries. The management of acute ischemic stroke has advanced great-
ly over the past 20 years. Now the treatment of stroke can be described with one word- variety.
The current review is dedicated to the problems of endovascular treatment in acute ischemic stroke. The dif-
ferent methods of treatment, pros and cons of each of them, discussing the different options for the patients 
are presented.  
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Every stroke centre worked based on some 
kind of protocols or administrative pathways, but at 
the moment there do not exist united positions for a 
lot of questions, related to stroke management. The 
main goal in treatment is to protect the penumbra 
(this is the area surrounding an ischemic event such 
as an ischemic, thrombotic or embolic stroke) by 
increasing oxygen transport and delivery to cells 
in the danger zone, thereby limiting cell death. The 
existence of a penumbra implies that salvaging of the 
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cells is possible. There is a high correlation between 
the extent of spontaneous neurological recovery and 
the volume of penumbra that escapes infarction. 
Therefore, saving the penumbra should improve the 
clinical outcome. Different studies are going at the 
moment, trying to determine the best way to save 
this fragile area and treat a patient with ischemic 
stroke. Although there are a lot of different opinions, 
also there exists some golden standards, which are 
applied in major stroke centers, such as intravenous 
(IV) thrombolysis.  
The era of endovascular therapy for acute 
ischemic stroke began with the first reported use of 
thrombolytic agents. Since the approval in 1996 by 
the United States Food and Drug Administration 
(FDA) of intravenous thrombolysis with recombinant 
tissue plasminogen activator (rtPA, alteplase) for the 
treatment of acute ischemic stroke is the standard 
treatment (3,6). Intravenous rt-PA in acute ischemic 
stroke should be undertaken in patients satisfying 
specific inclusion and exclusion criteria. It should be 
given as early as possible, because the effect size of 
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thrombolysis is time-dependent. Where it is possible, 
therapy should commence in the first few hours 
but may be used up to 4,5 hours after stroke onset. 
These procedures required appropriate hospital 
infrastructure, facilities and network support. Also 
IV rt-PA should be given under the authority of a 
physician trained and experienced in acute stroke 
management. For as much as there are specific 
criteria or protocol, IV thrombolysis cannot be 
performed in every patient with acute ischemic 
stroke. One of the main limitations to IV rtPA since 
its approval has been the strict at first 3-hour then 
4.5- hour time window for initiating therapy. This 
window, combined with a lack of public awareness 
of stroke, has unfortunately limited the use of IV 
thrombolysis to <5% of eligible candidates. So if the 
time window is passed, there are other possibilities 
for treatment such as IA trombolysis and other 
endovascular methods. 
Intra-arterial (IA) thrombolysis is an emerging 
treatment strategy for acute ischemic stroke. It was 
first described in 1983 by Zeumer et al. One hundred 
eighty patients with proximal middle cerebral artery 
(MCA) occlusions were enrolled and treated within 
6 hr of the onset of stroke. Additional inclusion 
criteria included a National Institutes of Health 
Stroke Scale score of 4 to 30 and lack of haemorrhage 
or early signs of infarction involving more than one-
third of the MCA territory on CT scans. Exclusion 
criteria included rapidly improving neurologic 
deficit or sustained blood pressure of >180/100. In 
IA thrombolysis, the cervicocephalic arterial tree 
is traversed with an endovascular microcatheter 
delivery system, the catheter port is positioned 
immediately within and adjacent to the offending 
thrombus, and fibrinolytic agents are infused 
directly into the clot. This delivery technique permits 
high concentrations of lytic agent to be applied to 
the clot while minimising systemic exposure. MRI 
studies have provided striking imaging evidence 
of the potential beneficial effects of IA therapy 
(12,15). As with other interventional techniques 
used in acute stroke, the major disadvantages to IAT 
include the relative complexity of the procedure, 
the level of required technical expertise, relatively 
selective availability, delays in initiating treatment, 
and the additional risks and expense of an invasive 
procedure compared with IVT. The risk of 
symptomatic intracerebral haemorrhage and limited 
time constraints associated with thrombolytic 
agents prompted a search for alternate means of 
recanalisation in acute ischemic stroke. In some 
cases, where the patient has excluding factors and it 
is impossible to perform IV or IA thrombolysis, or 
administrating the latter doesn’t show any result, we 
can use alternative treatment (18). 
There is still insufficient evidence to recommend 
the use of mechanical clot removal in routine 
clinical practice, but in coming years endovascular 
mechanical reperfusion techniques, is likely to be 
increasingly refined and validated and to become a 
widely accepted therapy for acute ischemic stroke. 
The MERCI (The Mechanical Embolus Removal 
in Cerebral Ischemia) retriever was the first stroke 
device to be approved by the FDA, and thus launched 
the era of mechanical thrombectomy.  „To restore 
blood flow in the neurovasculature by removing 
thrombus in patients experiencing ischemic stroke. 
Patients who are ineligible for treatment with IV-
rtPA or who fail IV-rtPA therapy are candidates 
for treatment” (5,8). The Penumbra system is the 
second (and so far, the last) FDA-approved device 
specifically developed for the purpose of clot 
removal in acute ischemic stroke (9,10). This system 
provides a dual approach to clot extraction using 
aspiration and debulking of the thrombus to reduce 
or eliminate the clot burden. This is followed by clot 
retrieval with a ring device if needed that engages the 
thrombus by capturing it in clasps with a cylinder 
that is then withdrawn during flow arrest. Now there 
are a lot of studies and compartments between the 
intravenous thrombolysis and mechanical device 
and intraarterial t-PA. But a lot of the questions are 
still unanswered, the time and the indications for 
each of the procedures are vague. 
On the other hand, it still remains the question 
of time management. For example, performing 
a carotid endarterectomy or stent placements in 
patients with ischemic stroke during the acute phaze. 
It is considered that the time between the second 
day and the second week is the most suitable for 
performing a carotid endarterectomy. 
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Carotid endarterectomy is still the golden 
standard for treatment of the carotid artery stenosis. 
But many studies have shown the feasibility and high 
efficacy of percutaneous transluminal angioplasty 
(PTA) in acute stroke (1,3).
The angioplasty and stent placement are most 
commonly used in patients with acute ischemic 
stroke and desiccation of carotid artery. Jovin et 
al achieved successful recanalisation in 23 of 25 
patients, which had emergency stent placement  on 
the extracranial internal carotid artery.  Brekenfeld 
et al treated 350 patients with intraarterial urokinase 
and noticed that recanalisation can be improved by 
angioplasty and stent implantation (2,3).
One of the most exciting recent developments in 
the interventional treatment of acute ischemic stroke 
was perhaps the use of self-expanding stents for 
flow restoration. The first prospective FDA-approved 
trial, Stent-Assisted Recanalization in Acute Ischemic 
Stroke, demonstrated 100% recanalisation rate in 
20 patients. At present, no time recommendation 
for initiation of endovascular treatment in acute 
ischemic stroke is available. A recent multicentre 
analysis was designed to identify variables that 
prolong „time to microcatheter,“ defined as the 
time interval from computed tomographic scan to 
microcatheter placement in the cerebral circulation 
(5,13,17).  
CONCLUSION
Nowadays the treatment of ischemic stroke 
has more options than ever. The possibility of 
catheter-based drug administration, mechanical 
embolectomy, and angioplasty with stent placement 
required strict indication and unified protocols. The 
time and the indications for each of the procedures 
are questions, without precise answers.  
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